A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples

被引:48
|
作者
Zwart, Wilbert [1 ,5 ]
Koornstra, Rutger [1 ]
Wesseling, Jelle [1 ,2 ]
Rutgers, Emiel [3 ]
Linn, Sabine [1 ,4 ]
Carroll, Jason S. [5 ,6 ]
机构
[1] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England
[6] Univ Cambridge, Dept Oncol, Cambridge CB2 OXY, England
来源
BMC GENOMICS | 2013年 / 14卷
基金
欧洲研究理事会;
关键词
TAMOXIFEN RESISTANCE; LIMITED NUMBERS; ALPHA; BINDING; CELLS;
D O I
10.1186/1471-2164-14-232
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: The Estrogen Receptor alpha (ER alpha) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ER alpha, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ER alpha binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue. Results: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing. Conclusion: We illustrate the applicability of this refined technology by mapping the ER alpha genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples.
引用
收藏
页数:7
相关论文
共 27 条
  • [1] A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
    Wilbert Zwart
    Rutger Koornstra
    Jelle Wesseling
    Emiel Rutgers
    Sabine Linn
    Jason S Carroll
    BMC Genomics, 14
  • [2] HMCan: a method for detecting chromatin modifications in cancer samples using ChIP-seq data
    Ashoor, Haitham
    Herault, Aurelie
    Kamoun, Aurelie
    Radvanyi, Francois
    Bajic, Vladimir B.
    Barillot, Emmanuel
    Boeva, Valentina
    BIOINFORMATICS, 2013, 29 (23) : 2979 - 2986
  • [3] Accuracy of Estrogen and Progesterone Receptor Assessment in Core Needle Biopsy Specimens of Breast Cancer
    Omranipour, Ramesh
    Alipour, Sadaf
    Hadji, Maryam
    Fereidooni, Forouzandeh
    Jahanzad, Issa
    Bagheri, Khojasteh
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2013, 15 (06) : 515 - 518
  • [4] Quantitative combinatory indexed ChIP-seq reveals distinct transcriptional complexes containing estrogen receptor and GREB1 at chromatin in breast cancer cells
    Sun, J.
    Lippman, M. E.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7
    Li, Qi
    Wang, Huichun
    Yu, Leyang
    Zhou, Jun
    Chen, Jingde
    Zhang, Xia
    Chen, Lin
    Gao, Yong
    Li, Qun
    TUMOR BIOLOGY, 2014, 35 (05) : 4779 - 4784
  • [6] Meta-analysis of integrated ChIP-seq and transcriptome data revealed genomic regions affected by estrogen receptor alpha in breast cancer
    Zeynab Piryaei
    Zahra Salehi
    Esmaeil Ebrahimie
    Mansour Ebrahimi
    Kaveh Kavousi
    BMC Medical Genomics, 16
  • [7] Meta-analysis of integrated ChIP-seq and transcriptome data revealed genomic regions affected by estrogen receptor alpha in breast cancer
    Piryaei, Zeynab
    Salehi, Zahra
    Ebrahimie, Esmaeil
    Ebrahimi, Mansour
    Kavousi, Kaveh
    BMC MEDICAL GENOMICS, 2023, 16 (01)
  • [8] Levels of estrogen receptor in breast cancer tissue can be significantly underestimated in specimens taken by core needle biopsy.
    Valik, D
    Nekulova, M
    Vondracek, V
    Jandakova, E
    Petrakova, K
    CLINICAL CHEMISTRY, 2002, 48 (06) : A13 - A13
  • [9] Histological malignancy grade, estrogen receptor and HER2 receptor status on core needle biopsy compared to surgical specimen in breast cancer - how accurate is it?
    Munch-Petersen, H. D.
    Balslev, E.
    APMIS, 2013, 121 : 8 - 8
  • [10] Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
    Arnedos, M.
    Nerurkar, A.
    Osin, P.
    A'Hern, R.
    Smith, I. E.
    Dowsett, M.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1948 - 1952